Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Drug:
agatolimod sodium
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
LYMNHL0014
, 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
2.
Phase?/? Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
20 to 80
Sponsor:
Other
Protocol IDs:
WEUTC
, NCT00669292
3.
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A8501006
, NCT00321815
4.
Phase II Study of Agatolimod Sodium and Trastuzumab (Herceptin®) in Patients With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OSU-08153
, OSU 08153, PFIZER-GA8501YF, 2008C0116, NCT00824733
5.
An Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
SU-03272009-2038
, LYMNHL0064, NCT00880581
6.
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
200402002
, NCT00233506
7.
Phase I Study of PADRE-CMV Fusion Peptide Vaccine or Tetanus-CMV Fusion Peptide Vaccine With or Without CpG 7909 Adjuvant in Healthy Participants Who Are Cytomegalovirus-Seropositive or -Seronegative
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 55
Sponsor:
NCI
Protocol IDs:
CHNMC-03121
, 03121, NCT00722839
8.
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-Derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-Expressing Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
05-140
, 1R01CA112198-01, NCT00819806
9.
Pilot Study of a Peptide Vaccine Comprising MART-1:27-35 Peptide, gp100:209-217 (210M) Peptide, and Tyrosinase Peptide With Sargramostim (GM-CSF) and CpG 7909 Emulsified in Incomplete Freund's Adjuvant in Patients With Unresectable Recurrent Stage III or IV Melanoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PCI-04173
, 04-173, PCI-IRB-0607048, 7357, NCT00471471
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute